Nxera Pharma (“Nxera” or “the Company; TSE 4565) announces that it has entered an exclusive licensing agreement for the development, manufacturing and commercialization of vamorolone for the treatment of Duchenne Muscular Dystrophy (DMD) in Japan, South Korea, Australia and New Zealand with Santhera Pharmaceuticals Holding (“Santhera”) Vamorolone is approved and marketed as AGAMREE for the treatment of DMD, a rare inherited neurodegenerative disease, in the US, European Union, UK and China.
Learn More: What is Agamree (vamorolone)? What is Agamree Used For?
- Vamorolone is approved and marketed as AGAMREE for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China
- New five-year data on vamorolone highlighted substantially improved safety profile with reduced vertebral fractures, lower incidence of cataracts and that normal growth rate was maintained. With adverse effects being a key limitation of conventional corticosteroid therapy, vamorolone’s safety profile combined its comparable effectiveness, has the potential to displace existing steroid treatments
- Transaction advances Nxera’s mission to bring innovative medicines to patients in Japan/APAC in line with 2030 vision to build high-growth, highly profitable Japanese biopharma company
Read More: Clinical Trials for Duchenne (List of All Researches)
- Follow Us -
